Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Follicular 8Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 3Leukemia, B-Cell 3Neoplasms 2Leukemia 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Melanoma 1Mature B-Cell Malignancies 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Hairy Cell 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

obinutuzumab 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Part1: Advanced B-cell Malignancies × obinutuzumab × Clear all
NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

AstraZeneca

Phase 1 Active not recruiting
35 enrolled
Lymphoid

Part1: Advanced B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡